Insight

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Photo from Razan Mohty/X

Aug 17, 2024, 07:45

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X about a recent paper published in BMT journal.

“Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT”

Authors: Razan Mohty et al.

“Check our newly published article on outcomes of patients with IDH1 or 2 mutated AML after alloHCT, a study of the ALWP of The EBMT in BMT journal.

Thank you Abdul-Hamid Bazarbachi, Mohamad Mohty, Myriam Labopin, and all co-authors.”

Source: Razan Mohty/X

More posts by Razan Mohty in OncoDaily.

Abdul-Hamid Bazarbachi Acute Myeloid Leukemia alloHCT ALWP AML BMT journal cancer Mohamad Mohty Myriam Labopin OncoDaily Oncology Razan Mohty The EBMT UAB Medicine

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage